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Abstract: Breast cancer persists as the most common cause of cancer death in women worldwide.
Ovarian cancer is also a significant source of morbidity and mortality, as the fifth leading cause
of cancer death among women. This reflects the continued need for further understanding and
innovation in cancer treatment. Though breast and ovarian cancer usually present as distinct clinical
entities, the recent explosion of large-scale -omics research has uncovered many overlaps, particularly
with respect to genetic and epigenetic alterations. We compared genetic, microenvironmental, stromal,
and epigenetic changes common between breast and ovarian cancer cells, as well as the clinical
relevance of these changes. Some of the most striking commonalities include genetic alterations of
BRCA1 and 2, TP53, RB1, NF1, FAT3, MYC, PTEN, and PIK3CA; down regulation of miRNAs 9, 100,
125a, 125b, and 214; and epigenetic alterations such as H3K27me3, H3K9me2, H3K9me3, H4K20me3,
and H3K4me. These parallels suggest shared features of pathogenesis. Furthermore, preliminary
evidence suggests a shared epigenetic mechanism of oncogenesis. These similarities, warrant further
investigation in order to ultimately inform development of more effective chemotherapeutics, as well
as strategies to circumvent drug resistance.
Keywords: breast cancer; ovarian cancer; epigenetics
1. Classification of Breast and Ovarian Cancer
Globally, breast cancer persists as the most common cause of cancer death in women, and the
leading cause of death in women ages 40–49. Despite an over 95% sensitivity of current breast cancer
screening, overall mortality has decreased by only 30%. Though less common, ovarian cancer is the
fifth leading cause of cancer death in women in the US, owing both to its virulence, and our lack
of effective screening. This reflects the continued, if not dire, need for further understanding and
innovation in these respective fields of cancer treatment.
This need for more efficacious screening and therapeutics has fueled a rapidly evolving body of
scientific work. This has led to an emerging understanding that these clinical entities encompass many
heterogeneous cancers, resulting in a new classification schema. Breast cancer tumors were classically
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categorized by histological origin into infiltrating ductal (76%), invasive lobular (8%), ductal/lobular
(7%), mucinous/colloid (2.4%), tubular (1.5%), medullary (1.2%), and papillary (1%). New definitions
have simplified the sub groups as luminal A, luminal B, hormone receptor positive and triple negative,
which more closely parallels clinical treatment algorithms.
This new schema also aligns with ovarian cancer classification, which includes surface, germ,
stromal, and borderline tumors. Of these groups, epithelial carcinomas account for the vast majority
(over 90%) and can be divided into serous I, serous II, endometroid, mucinous, Brenner, and
clear cell [1]. Based on molecular markers, ovarian tumors can be further classified into Type I
versus Type II tumors. Type I, or low-grade serous carcinoma, is associated with a ~55% 5 years
survival. These tumors develop via the stepwise accumulation of carcinogenic modifications, including
BRAF/KRAS. Type II tumors, on the other hand, are often high-grade serous carcinomas (~30%
five years survival) at the time of presentation and are associated with various shared patterns of gene
expression, as well as frequent p53 mutations. Interestingly, in both breast and ovarian cancer, the vast
majority of tumors are of epithelial origin; less commonly, tumors arise from functional and stromal
cells. This is further supported by the emerging body of evidence that a significant subset of ovarian
cancers in fact originate in the fallopian tubes, adding to the epithelial predominance [1].
2. Comparison of the Genetic and microRNA Environments of Breast and Ovarian Cancer
Though breast and ovarian cancer are more often distinct clinical entities, the recent explosion of
genomics, proteomics, metabolomics, and other large-scale-omics research, has uncovered many
overlaps between the two, including what we and others posit to be relevant shared genetic
alterations [2]. These similarities are particularly striking between epithelial-origin triple negative
basal cell breast cancer (TNBC) and high-grade serous ovarian cancer (HGS-OvCa). A summary of
common mutations in breast and ovarian cancers is listed in Table 1.
Table 1. Comparison of significant genetic alterations in breast and ovarian cancers.
Gene Type Gene Function Breast Ovarian
BRCA1/2 [3–5] Mutation DNA homologous recombination repair Yes Yes
TP53 [1,3,5] Mutation Cell cycle checkpoint Yes Yes
RB1 [3,5] Mutation/Deletion Cell cycle regulator Yes Yes
NF1 [3,5] Mutation/Deletion Negative regulator cell division via Ras inhibition Yes Yes
FAT3 [3,5,6] Mutation Central nervous system development Yes Yes
CSMD3 [3,5,7] Mutation,Copy Number Development - Yes
GABRA6 [5] Mutation GABA receptor, neurons - Yes
CDK12 [5,8] Mutation RNA splicing regulation - Yes
BRAF [5] Mutation Proto-oncogene, cell growth signals - Yes
PIK3CA [3,5] Mutation Cell growth, Catalytic subunit of PI3k,signaling cascades including activation of Akt Yes Yes
KRAS [5] Mutation Cell growth, Signal propagation includinggrowth factor and PI3k signals - Yes
NRAS [5] Mutation Cell growth, Signal propagation includinggrowth factor and PI3k signals - Yes
CCNE1 [5,9] Copy NumberAmplification Cycle E1—cell cycle regulation - Yes
MYC [3,5] Copy NumberAmplification
Txn factor, involved in cell cycle progression and
apoptosis Yes Yes
MECOM [5,10] Copy Number Amp Differentiation, apoptosis, stem cell quiescence [6] - Yes
ZMYND8 [5,11] Copy Number Amp C-kinase receptor, possibly involved in DNAdamage recognition [7] - Yes
IRF2BP2 [5] Copy Number Amp P53 target - Yes
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Table 1. Cont.
Gene Type Gene Function Breast Ovarian
ID4 [5,12] Copy Number Amp Transcription inhibition development, growthdifferentiation, senescence, apoptosis, angiogenesis - Yes
PAX8 [5,13] Copy Number Amp Development - Yes
TERT [5] Copy Number Amp Telomerase, genome stability - Yes
PTEN [3,5] Deletion cell cycle and apoptosis, possibly migration,adhesion, and angiogenesis Yes Yes
CREBBP [5] Deletion Cell cycle control Yes
AKT1 [3] Apoptosis Yes -
GATA3 [3,14] Mutation Differentiation of luminal cells, EstrogenReceptor pathway Yes -
CDH1 [3] - Cell adhesion, cell cycle regulation Yes -
MLL3/KMT2C [3,15] - Demethylation of H3K27, differentiation Yes -
MAP3K1 [3] - MAPK/ERK pathway-cell cycle Yes -
CDK1B [3] - Cell cycle progression Yes -
TBX3 [3,16] Mutation Mammary gland development Yes -
RUNX1 [3] - Development and differentiation, hematopoiesis Yes -
CBFB [3] - Development, stem-cell homeostasis Yes -
AFF2 [3,5,17] - Cell proliferation Yes Yes
PTPN22 [3] - Immune signaling, responsiveness of T and B cells Yes -
PTPRD [3] - Cell cycle, growth, differentiation Yes -
SF3B1 [3] - Splicing Yes -
CCND3 [3] - Cell cycle Yes -
As one might expect, the seemingly disparate genetic alterations are directly or indirectly related to
cell cycle control, growth, development, differentiation, DNA damage repair, and apoptosis (Figure 1).
Thus, it follows that many of these key genetic alterations have been found in multiple types of cancer,
in addition to breast and ovarian [18].
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The Human Cancer Genome Atlas, an extensive study investigating gene copy numbers, exon 
sequences, DNA methylation, and the expression of miRNA, and proteins in breast cancer tumors, 
identified numerous common genetic alterations among seemingly heterogeneous breast cancers. 
For example, TP53, PIK3CA, and GATA3 mutations occurred at an incidence greater than 10% 
across all breast cancers. When separated into molecular subtypes, more commonalities were 
identified. In basal-like tumors and TBNC (ER-, PR-, HER2-), RB1, BRCA1, and TP53 commonly 
contained loss-of-function mutations [3]. Interestingly, these mutations are also prevalent in 
HGS-OvCa tumors [5]. Although mutations in these genes are often found in cancers, the high 
frequency at which mutations in RB1, BRCA1, and TP53 occur in TNBC and HGS-OvCa may 
indicate molecular similarities in the development or progression of these two different, aggressive 
cancers [3]. 
By far, the most commonly mutated gene in both TNBC and HGS-OvCa is TP53. The Cancer 
Genome Atlas found that TP53 was mutated in 80% of TNBC tumors and 96% of HGS-OvCa tumors 
analyzed [3]. Other groups have reported a similarly high prevalence of TP53 mutations in these and 
other aggressive cancer subtypes [2,3,19] compared to the lower frequency of somatic TP53 
mutations seen in many other cancers. For example TP53 mutations have been identified in 27% of 
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The Human Canc r Gen me Atlas, an extensive study investigati g gen copy numbers, exon
sequences, DNA ethylation, and the expression of miRNA, and proteins in breast cancer tumors,
identified numerous common genetic alterations among seemingly heterogeneous breast cancers.
For example, TP53, PIK3CA, and GATA3 mutations occurred at an incidence greater than 10% across
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all breast cancers. When separated into molecular subtypes, more commonalities were identified.
In basal-like tumors and TBNC (ER-, PR-, HER2-), RB1, BRCA1, and TP53 commonly contained
loss-of-function mutations [3]. Interestingly, these mutations are also prevalent in HGS-OvCa
tumors [5]. Although mutations in these genes are often found in cancers, the high frequency at
which mutations in RB1, BRCA1, and TP53 occur in TNBC and HGS-OvCa may indicate molecular
similarities in the development or progression of these two different, aggressive cancers [3].
By far, the most commonly mutated gene in both TNBC and HGS-OvCa is TP53. The Cancer
Genome Atlas found that TP53 was mutated in 80% of TNBC tumors and 96% of HGS-OvCa tumors
analyzed [3]. Other groups have reported a similarly high prevalence of TP53 mutations in these and
other aggressive cancer subtypes [2,3,19] compared to the lower frequency of somatic TP53 mutations
seen in many other cancers. For example TP53 mutations have been identified in 27% of brain tumors
and 5.8% of cervical cancers [20]. An extensively studied gene, TP53, encodes the transcription factor
p53, a protein involved in many signaling pathways that halt cell cycle progression, activate DNA
repair mechanisms, and induce apoptosis when activated in response to cellular stress [19,21,22]. Thus,
as an anti-proliferative or even pro-apoptotic protein, p53 acts as an important tumor suppressor gene
in response to DNA damage. In the context of cancer, it is apparent that tumors with mutations in
TP53 are more susceptible to retaining and passing down DNA damage, allowing for the selection
of more aggressive tumors. The significance of the shared, high TP53 mutation rate in TNBC and
HGS-OvCa is striking and suggestive of shared fundamental features of pathogenesis.
Another commonly mutated gene in breast and ovarian cancers, functional BRCA1 protects the
cell from double-stranded DNA damage through homologous recombination. BRCA1/2 mutations
are present in 5%–15% of all breast and ovarian cancers [3–5] and have been found in other hereditary
diseases [23–26], in the absence of homolous recombination, cells are more vulnerable to genomic
instability. Accordingly, cancers containing mutations in BRCA1 have numerous copy number
aberrations (CNAs) and are more likely to be TNBC or HGS-OvCa. Interestingly, many BRCA1-mutated
TNBC show characteristic patterns in CNAs leading to the classification of BRCA1-mutated cancers
as BRCA1-like or non-BRCA1-like TNBC [27,28]. These and other studies comparing copy number
landscapes of breast and ovarian cancers have reported several common features between TNBC
tumors and HGS-OvCa tumors, including common gains within 1q, 3q, 8q, and 12p (in particular
HIF1A and MYC) and loss within 4q, 5q, 8p, and 10q (in particular FOXA1, ER, and PTEN) [28].
3. Comparison of the Respective MicroRNA Environments
In addition to coding-DNA mutations, breast and ovarian cancers contain an array of miRNA
expression alterations, which contribute to the development and progression of cancer [29]. In healthy
cells, miRNA regulate mRNA stability, ensuring proper timing in the formation of functional
proteins. Thus, when misregulated, miRNAs can lead to improper protein translation. Table 2
lists misregulated miRNAs implicated in breast and ovarian cancers, respective gene targets and
the functional implications in cancer. For example, miR-100, miR-214, miR-206, and miR-233 are
involved in diverse pro-growth and anti-apoptotic pathways. miR-100 targets the pro-growth proteins
FRAP1/mTOR and FGFR3 for degradation and when downregulated, these genes are re-expressed and
function as oncogenes (Figure 2A, [30–42]). miR-214 deregulation induces cell survival and cisplatin
resistance. In breast cancer, downregulation of miR-214 leads to increased EZH2 expression which
causes increased cell proliferation [32]. EZH2 is an important epigenetic regulator that positively
regulates insulation zone formation for selective gene silencing by enhancing H3K27me3. In ovarian
cancer, miR-214 targets PTEN, leading to activation of the Akt cell survival pathway. Akt inhibitors
have been found to nullify miR-214 induced cell survival [32]. Interestingly, EZH2 is a part of the
polycomb group of proteins that helps to regulate gene expression during normal development. On the
other hand, miR-206 is upregulated in breast cancer and targets the ERα gene [41].
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Table 2. miRNA implicated in breast and ovarian cancers.
miRNA Up-/Downregulated Gene Target Gene Activity Breast Cancer? Ovarian Cancer? Function
miR-100 [29] Down FRAP1/mTOR, FGFR3 [30] - Yes Yes Cell growth and survival
miR-9 [31] Down
FGF18, FGF10, BCL2, BCL6,
BRAF, CLDN14, CLDN6,
SEPTIN10, ZNF, PVRL2,
LASS4, BCL2, CLDN, FGF
- Yes (miR-9-3) Yes Drug resistance
miR-214 [29,32] Down PTEN, EZH2 Suppression Yes Yes Cell survival, cisplatin resistance, Akt
miR-125a [33] Down HER2, ARI3B Suppression Yes Yes EMT
miR-125b [33] Down HER2 Suppression Yes Yes EMT
miR-22 [34,35] - miR-20 - Yes - Metastasis
miR-34c [36] Down - - - - EMT
miR-199a [37] Down - - - Yes
miR-200a [38] Down(EMT)/Up(MET) ZEB2 Suppression - Yes EMT
miR-200c [38] Down(EMT)/Up(MET) ZEB1/2 Suppression - Yes EMT
miR-146a Up (variant allele) BRCA1/2 - - Yes -
miR-210 [39] Down (CNA) E2F3 (TxF) - - Yes HIF
miR-233 [40] Up
FGFR2, EGF, S100A3, KRAS,
TGFB2, IFNBI, SPINKS, E2F1,
SEPTIN6, MMP9, USF2
- - - Ras, integrin signal
miR-206 [33,41] Up ERα Suppression Yes - -
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As shown in Table 2, several miRNAs are also involved in the increased invasiveness of breast
and ovarian cancers and the development of higher grade tumors. For example, the do nregulation of
miR-9-3, is implicated in breast cancer metastasis, vascular invasion, angiogenesis, a d drug resistance
dev lopment [31,40]. miR-9 expression downregulates BCL2, BCL6, FGFR10, F F 8 and BRAF,
which are involved in a ti-apoptosis, cell-gr wth, and differe tiat on. Downregulation of miR-9
upregulates these pathway (Figure 2B, [43]).
Additionally, miR-23 d l t s FGFR2 and EGF, w ich are involved in cell growth
an differentiation, as well as TGF-β2 and IFNB1, which are involved in apoptosis. miR-233 is
upregulated in ovarian cancer, downregualting these path ays (Figure 2C, [44]). Other miRNAs,
including miR-34c, miR-125a, miR-125b, miR-200a, and miR-200c, are downregulated during the
epithelial-to-mesenchymal (EMT) transition in ovarian cancer cells [45–48]. Downregulation of
miR-34c, miR-125a, and miR-125b also induces EMT in breast cancer-initiating cells [36]. In particular,
miR-34c gene down-regulation via DNA methylation has been shown to promote self-renewal and
EMT in breast tumor-initiating cells [36]. Downregulation of miR-125a suppresses ARID3B, a gene
which is overexpressed in human ovarian cancer [49]. Furthermore, sequence alternations in miRNAs
interact pathologically with BRCA1 and BRCA2. For example, a polymorphism found within the
miR-146a sequence has been found to alter the stem region of this miRNA from G:U to C:U. This variant
allele produces more mature miR-146a than the wild-type, and the mutant variant has a significantly
stronger binding capability to its target BRCA1 and BRCA2 mRNA sequences, which are, themselves,
arguably the most studied shared mutations of breast and ovarian cancer [50].
4. Epigenetic Comparison of Breast and Ovarian Cancer
In addition to genetic alterations and iR , breast and ovarian cancers frequently share key
epigenetic patterns. Research has identified co siste t et lation patterns that often precede breast
cancer progression. For example, moderate to low levels of lysine acetylation (H3K9ac, H3K18ac,
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and H4K12ac), lysine methylation (H3K4me2 and H4K20me3), and arginine methylation (H4R3me3)
were observed in HER2-positive tumors [51]. Similar data with respect to ovarian cancer is still
emerging. The level of histone methylation depends on the activation or deactivation of specific
histone methylases or demethylases, and alterations of the methylation status of histones has been
clearly demonstrated in breast cancer [52,53]. In the case of ovarian cancers, histone splicing is
observed. For example, alternative splicing of H2A type histone variants have been observed in
ovarian cancers. Additionally, investigations on nuclear dynamics changes are currently underway
in ovarian cancer [54] and breast cancer [55]. Importantly, common histone methylation patterns in
breast and ovarian cancer include H3K27me3, H3K9me2, H3K9me3, H4K20me3, and H3K4me. In fact,
Elisheikh et al. [51] have found a consistent correlation between H4K16me3 and 78.9% of all breast
cancers. Recent studies showed that mutation of DNA methylases can increase methylation of specific
lysine residues in histone 3, causing changes which favor carcinogenesis [56]. For example, the DNA
methyltransferase EZH2, which causes H3K27me3, is mutated in breast cancer [56]. Interestingly,
H3K27me3 recruits the CCCTC motif binding protein CTCF, which creates an insulation zone and
inhibits enhancer and promoter interactions to silence specific genes during development [57–59].
These interactions are disrupted by DNA methylation around the interacting sites. For example, in
breast cancer, histone modifications at enhancers were observed to regulate genes even up to 750 kilobase.
In addition, about 50% of active enhancers were found in nucleosome depleted regions. Expression data
analysis identified 600 active enhancers. The genes regulated by these enhancers have functions which
include proteolysis, epidermis development, cell adhesion, mitosis, cell cycle, and DNA replications [55].
In addition to histone modifcations, global modification of DNA sequences by methylation at
CpG residues plays an important role in oncogenesis of both breast and ovarian cancer. As described
above, methylation of the enhancer sites reverse CTCF regulated DNA silencing [60], but methylation
of specific CpG islands in the promoter regions of genes silence them [61,62]. Shared targets of
methylation include the promotor regions of p21, p16, MGMT, BRAC1, MLH1, HOXD11, CDH1
(E-cadherin), TGF-R, ARHI, and RASSF1A in breast and ovarian cancer [63].
In the case of breast cancer, 30% of tumors are associated with an overexpression of HER2
due to amplification of gene copy number [64]. Interestingly, overexpression of HER2-mediated
signaling has been shown to alter the genome-wide methylation pattern [65,66]. Specifically, the
genes most commonly methylated in these tumors were relevant to development and transcription
(AKT3, HK1, PFKP, AKR1B1, INA, FOXC2, NEUROD1, CDKL2, IRF4) or were Homeobox genes
(DBX1, NX-6, SIX6) [67]. Other well-known drivers of breast cancer metastasis include upstream
methylation of E-cadherin, RARRF1A, RAR-2, APC, TWIST, and GSTP1 [68]. Another important
example, cell adhesion receptor integrins including α5β6, may also regulate methylation in breast
cancer cells [69,70]. Interestingly, it has been shown that HER2 and integrin receptors associate to
enhance downstream signaling for breast cancer progression [71]. It is reasonable to believe that these
downstream signaling processes regulate DNA methylation. In support of this notion, a recent study
showed that ERK kinase regulated DNA Methyltransferase 1 (DNMT1) and methylation of specific
genes in prostate cancer cells [72]. In addition to ERK, Akt DNA methylation also regulates H3K27me3
mediated gene silencing [73]. This suggests that intracellular signaling plays a significant role in the
methylation process regulating gene silencing. Usually, DNMTI is highly expressed in cancer cells
compared to normal cells where its expression varies at different stages of the cell cycle [74]. A recent
system biology study showed that higher expression of DNMTI does not necessarily methylate and
silence all types of genes in cancer cells. DNMTI is allosterically activated at the locations of genes it
silences [75]. Taken together, this suggests a complicated but well-orchestrated mechanism by which
methylation and thereby gene silencing are regulated. Changes in the balance can, thus, perturb
epigenetic regulation and gene expression.
Figure 3 depicts a simplistic model of possible epigenetic regulation of tumor suppressor
genes and growth promoting genes in breast and ovarian cancer progression. Many of the
epigenetically-regulated genes are common in both types of cancers and some are different but the
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regulation could be similar. Hypermethylation of promoter regions blocks POLII binding inhibiting
transcription of tumor suppressor genes (Figure 3A). As this process is reversible, when these regions
are demethylated by treatment with epigenetic drugs, POLII binds and tumor suppressor genes are
re-expressed (Figure 3B), which is an important aspect of current improvement as combination therapy.
In contrast, growth promoting genes are kept under controlled expression by CTCF binding to the
H3K27me2/me3 regions creating an insulation zone and inhibiting enhancer-promoter interaction
necessary for POLII binding and transcription initiation (Figure 3C). In both breast and ovarian
cancer this control could be lost because of hypermethylation around the region where CTCF binds
(Figure 3D), which causes an above normal expression of growth promoting genes. Demethylation as
a result of epigenetic drug treatment, allows CTCF to bind in these regions controlling above normal
growth promoting gene expression. Since the formation of breast cancer or ovarian cancer progenitor
cells is a long term process, gradual epigenetic changes which cause alteration of gene expression
slowly convert a few pre-disposed cells to breast or ovarian cancer progenitor cells. Other genetic
alterations help advance and speed up this progression. Overall, this model shows that a change
of balance in CpG DNA methylation in upstream promoter regions and in enhancers along with
differential histone methylations regulates the initial steps in tumorigenesis. Although not currently
included in this model, histone modifications, such as H3K4, are known to facilitated gene expression.
Additionally, lnc RNA may also have a role in this process [76]. However, future studies will reveal
how much these factors contribute to the described model.
Int. J. Mol. Sci. 2016, 17, 759 8 of 17 
 
regulation could be similar. Hypermethylation of promoter regions blocks POLII binding inhibiting 
transcription of tumor suppressor genes (Figure 3A). As this process is reversible, when these 
regions are demethylated by treatment with epigenetic drugs, POLII binds and tumor suppressor 
genes are re-expressed (Figure 3B), which is an important aspect of current improvement as 
combination therapy. In contrast, growth promoting genes are kept under controlled expression by 
CTCF binding to the H3K27me2/me3 regions creating an insulation zone and inhibiting 
enhancer-promoter interaction necessary for POLII binding and transcription initiation (Figure 3C). 
In both breast and ovarian cancer this control could be lost because of hypermethylation around the 
region where CTCF binds (Figure 3D), which causes an above normal expression of growth 
promoting genes. Demethylation as a result of epigenetic drug treatment, allows CTCF to bind in 
these regions controlling above normal growth promoting gene expression. Since the formation of 
breast cancer or ovarian cancer progenitor cells is a long term process, gradual epigenetic changes 
which cause alteration of gene expression slowly convert a few pre-disposed cells to breast or 
ovarian cancer progenitor cells. Other genetic alterations help advance and speed up this 
progression. Overall, this model shows that a change of balance in CpG DNA methylation in 
upstream promoter regions and in enhancers along with differential histone methylations regulates 
the initial steps in tumorigenesis. Although not currently included in this model, histone 
modifications, such as H3K4, are known to facilitated gene expression. Additionally, lnc RNA may 
also have a role in this process [76]. However, future studies will reveal how much these factors 
contribute to the described model. 
 
Figure 3. Model of DNA methylation and histone methylation regulating gene expression for breast 
and ovarian cancer initiation. (A,B) Hypermethylation is indicated by red balls (CpG residue). White 
balls represent unmethylated CpG residues. DNMT1 represents DNA methyl transferase 1, POLII 
represents RNA polymares II; (B) In the absence of hypermethylation, POLII is able to bind to the 
promoter region and initiate transcription; (C,D) White balls represent unmethylated, and red balls 
represent hypermethylated CpG residues. CCCTC is CTCF binding motif. The green circle 
represents effective insulation zone. Break of insulated zone is shown by dotted green circle. 
5. Role of Stroma in Breast and Ovarian Cancer 
Epigenetic regulation originates both intracellularly and extracellularly. Stromal cells are 
central to this process, providing extracellular signals, and inducing intracellular changes via 
cell-cell interactions. As described above, signaling pathways (e.g., ERK and AKT) regulate 
methylation. Cytokines, growth factors, and hormones from the extracellular milieu, as well as 
Figure 3. Model of DNA methylation and histone methylation regulating gene expression for breast and
ovarian cancer initiation. (A,B) Hypermethylation is indicated by red balls (CpG residue). White balls
represent unmethylated CpG residues. DNMT1 represents DNA methyl transferase 1, POLII represents
RNA polymares II; (B) In the absence of hypermethylation, POLII is able to bind to the promoter
region and initiate transcription; (C,D) White balls represent unmethylated, and red balls represent
hypermethylated CpG residues. CCCTC is CTCF binding motif. The green circle represents effective
insulation zone. Break of insulated zone is shown by dotted green circle.
5. Role of Stroma in Breast and Ovarian Cancer
Epigenetic regulation originates both intracellularly and extracellularly. Stromal cells are central to
this process, providing extracellular signals, and inducing intracellular changes via cell-cell interactions.
As described above, signaling pathways (e.g., ERK and AKT) regulate methylation. Cytokines, growth
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factors, and hormones from the extracellular milieu, as well as direct attachment of stromal cells to
breast or ovarian epithelial cells, regulate intracellular signaling. The relationship between stromal
mutations and carcinogenesis is well known [14,68,77]. Furthermore, ovarian cancers have been
associated with higher numbers of fibroblasts, lymphocytes and other inflammatory cells. These cell
types may receive deranged regulatory signals from surrounding pathological cells. For example,
it has been shown that ovarian surface epithelial cells that have been immortalized by Ras may
reprogram the stromal microenvironment through the senescence of fibroblasts, and through this
mechanism, support tumorigenesis [77]. Furthermore, expression of the chemokine CXCR4 has been
found in 59% of ovarian cancers, and CXCL12 in 91% of ovarian cancers; both have been associated
with decreased disease free survival [78]. Finally, as with tumor genomes, studies have shown that
methylation levels are elevated in oncogenic breast stromal environments, often even before there
are detectable tumors [79]. Taken together, these examples support the notion that stromal changes
produce alterations in signaling that lead to increased methylation and histone modifications, which in
turn drives the formation of cancer progenitor cells (Figure 3). Although breast and ovarian stromal
environments are morphologically and functionally distinct, there are many shared common epigenetic
signaling pathways. Furthermore, as previously discussed, continued study of the fallopian (epithelial)
origin of various ovarian cancers my further our understanding of the pathogenicity of the respective
stromal environments.
6. Current and Future Treatment of Breast and Ovarian Cancer
In the case of breast cancer, clinical management is primarily driven by the hormonal and receptor
status of the tumor, as well as stage and grade. At this time, the standard of care necessitates genetic
testing of all breast cancer tumors. In both hormone receptor positive and negative tumors, standard
treatment begins with surgical excision, then local radiation, and finally chemotherapy guided by
the specific genetic diagnosis. Common agents include Tamoxifen (estrogen receptor antagonist),
Herceptin (HER2 inhibitor), and proteasome inhibitors. Thus, in breast cancer, depending on the
origin or the classification, target-specific drugs are part of the standard of care. In patients that have
an underlying predisposition to cancer, prophylactic surgery may also be considered.
The clinical manifestations of ovarian cancer are distinct among the gynecological malignancies
in that there is no standard screening protocol, and at best, subtle clinical signs; diagnosis can only
be confirmed by surgery. As such, at the time of presentation, the vast majority of neoplasms have
metastasized beyond the pelvis (grade III). Management includes surgical debulking, followed by
systemic chemotherapy. Since most cancers have metastasized before presentation, local radiation is
not the norm, except in select clinical scenarios including noninvasive tumor subtypes such as benign
teratomas. Standard regimens often include an intercalating agent, an alkalating agent (e.g., cis-platin,
carboplatin), an anti-growth agent (e.g., vincristine) and in some cases an anti-tetrahydrofolate
reductase (e.g., methotrexate). In contrast to breast cancer, chemotherapies used in the management of
ovarian cancer are often not target specific.
7. Drug Resistance
One of the major problems associated with breast and ovarian cancer chemotherapeutics is
the development of drug resistance. Clinically, this manifests as frequent relapse, and even more
importantly, relapse of tumors of higher virulence and intractability. For example, although most
women with advanced stage ovarian cancer initially respond to cytoreductive surgery and platinum
based chemotherapy, over 70% of women relapse. Moreover, platinum-resistant epithelial ovarian
cancer is considered uniformly fatal [79]. There are numerous pathways by which tumors may
gain drug resistance, including efflux by p-glycoproteins (MDR gene overexpression), rapid drug
metabolism, and alteration of the target site. In addition to traditional selective mechanisms, recent
studies have indicated that methylation plays a significant role in this process [80–82]. For example,
ER-i has been associated with tamoxifen resistance, and is methylated in 50% of breast cancers [83,84].
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Methylation of the MCJ gene has been associated with poor response to therapy, and poor overall
survival [85]. Demethylation of Fanconi anemia complementation group F (FANCF) with decitabine
has been shown to decrease sensitivity to cisplatin in various cell models [15]. Methylation of hMLHI
(a DNA mismatch repair protein) and subsequent loss of expression is associated with resistance
to cis-platin [85]. Importantly, demethylation and, thus, reversal of this and other pathological
modifications, has been associated with resensitization to therapy [86]. These various examples are
supported by the more general observation that DNMT1 inhibitors (AZA derivatives) and histone
deacetylase inhibitors (HDACi) have been shown to resensitize resistant ovarian cancer cells to cisplatin
by demethylation and re-epression of the RGS10 [87,88]. Though epigenetic changes are observed in
breast and ovarian cancers, no systematic study has been performed to compare the global methylation
status before versus after remission of both types of cancers.
Drawing inferences from similar studies in leukemia patients in which methylation levels
remained high throughout treatment, it is likely that a durable chemotherapeutic response will require
treatment that includes agents that modify global methylation and, thus, attack cancer progenitor
cells [61,81,84,89,90]. Furthermore, these agents must have the capacity to modulate chromatin opening,
as well as inhibit CpG methylation, in order to render drug resistant cells vulnerable to treatment, while
at the same time inhibiting the formation of new cancer progenitor cells. In support of this notion, it has
been shown that HDAC inhibitors (Class I and Class III) possesses the ability to successfully perform
both of these functions [90]. When these agents are combined with traditional chemotherapeutics,
even in suboptimal doses, they produce additive, or even synergetic death of breast and ovarian cell
lines [91,92].
Several clinical trials of such combination therapies are underway. It has been demonstrated
by these authors and others that the efficiency of demethylation increases when HDACi are used in
combination with DNMT1i [61,88–93]. Others have shown that such combinations are highly effective
against breast cancer in mouse models [94]. Furthermore reversal of platinum drug resistant ovarian
cancer after treatment with HDACi [88], and similarly reduction in the relapse of lung cancer patients
with use of epigenetic chemotherapeutics, have been reported [95]. As chemotherapy of ovarian cancer
is mainly target non-specific, and because epigenetic modifications possibly play similar types of roles
in ovarian and breast cancers, current investigators are extremely encouraged to develop epigenetic
therapies in combination with traditional drugs for breast and ovarian cancers. [50,61,62,91,92,94,96–99].
8. Inferences from a Comparison of Breast and Ovarian Cancer: An Epigenetic Link
Research continues to reveal that breast and ovarian cancer have a surprising number of shared
genetic, stromal, and epigenetic features, despite profoundly different clinical presentations. This has
led us to consider shared features of pathogenesis. Amidst the seemingly profound heterogeneity of
breast cancers, it has been suggested that all solid tumors may originate from 2 to 3 types of breast
cancer stem cells [2,3,100]. This is at odds with the classical notion that breast cancer development
is driven from myriad distinct genetic alterations. Rather, it is suggestive of a shared pathogenic
mechanism, which is then followed by the generation of diverse passenger mutations. There is
a significant body of indirect evidence that the shared mechanism for these discrete cancer events is
epigenetically driven. For example, methylation increases in breast and ovarian stromal cells prior
to carcinogenesis. This may suggest that oncogenesis is driven by expression of stromal signaling
molecules, which in turn induces epigenetic changes in target breast or ovarian cells, as described
in previous sections [50,101]. Furthermore, it has been reported that cancer progenitor cells are only
irradiated when treated with epigenetic modulating drugs [2]. Therefore, further research is likely to
reveal that the most significant commonalities between breast and ovarian carcinogenesis are shared
anteceding and perhaps causational patterns of epigenetics.
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AKR1B1 Aldo-keto reductase family 1, member B1
APC Adenomatous polyposis coli
ARHI Aplysia ras homology member I (GTP binding protein Di-RAS3)
ARID3B AT-rich interactive domain-containing protein 3B
CBFB Core-binding factor subunit beta
CDH1 Cadherin-1
CDK Cyclin kependent kinase
CDKL2 Cyclin-dependent kinase-like 2
CREBBP CREB-binding protein
DBX1 developing brain homeobox protein 1
DNMT DNA methyltransferase
DNMTi DNA methyltransferase inhibitor
EGF Epidermal growth factor
EMT Epithelial mesenchymal transition
ER Estrogen receptor
ER- Estrogen receptor negative
EZH2 Enhancer of zeste homolog 2
FANCF Fanconi anemia complementation group F
FGF Fibroblast growth factor
FGFR Fibroblast growth factor receptor
FRAP1 FK506-binding protein 12-rapamycin-associated protein 1 (Mammalian target of
rapamycin, MTOR)
GABRA6 Gamma-aminobutyric acid receptor subunit alpha-6
GSTP1 Glutathione S-transferase P
HDACi Histone deacetylase inhibitor
HGS-OvCa high-grade serous ovarian cancer
HIF Hypoxia induced factor
HK1 Hexokinase-1
IRF2BP2 Interferon regulatory factor 2-binding protein 2
IRF4 interferon regulatory factor 4
KMT2C Lysine N-methyltransferase 2C (Mixed-lineage leukemia protein 3, MLL3)
MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1
MDR Multidrug resistant
MECOM MDS1 and EVI1 complex locus protein EVI1
MGMT O-6-Methylguanine-DNA methyltransferase
miR microRNA
miRNA microRNA
MLH1 MutL homolog 1
MMP9 Matrix metallopeptidase 9
NEUROD1 Neuronal differentiation 1
NF1 Neurofibromin 1
PAX8 Paired box gene 8
PFKP Phosphofructokinase, platelet
PIK3 Phosphatidylinositol-4,5-bisphosphate 3-kinase
PTEN Phosphatase and tensin homolog
PTPRD Protein tyrosine phosphatase, receptor type D
PVRL2 Poliovirus receptor-related 2
RASSF1A Ras association domain-containing protein 1
RB1 Retinoblastoma 1
RUNX1 Runt-related transcription factor 1
SF3B1 Splicing factor 3B subunit 1
TERT Telomerase reverse transcriptase
TGF Transforming growth factor
TNBC triple negative basal cell breast cancer
TxF Transcription factor
USF2 Upstream stimulatory factor 2
ZEB Zinc finger E-box-binding homeobox 1
ZMYND8 Protein kinase C-binding protein 1
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